Vimian Group (VIMIAN) Q2 2025 earnings summary

Executive summary

• Leadership changes announced: CEO Patrik Eriksson departs, Carl-Johan Zetterberg Boudrie appointed interim CEO; Guy Sporri to leave MedTech, with Alireza Tajbakhsh assuming interim leadership.

• Board affirms confidence in current strategy, emphasizing organic and M&A-driven growth, and targets for 2025 and 2030.

• Revenue grew 15% year-over-year to EUR 104.3m in Q2 2025, with 5% organic growth, despite MedTech underperformance due to US orthopedics softness and negative currency impact.

• Adjusted EBITA increased 3% to EUR 25.4m; margin declined to 24.3% from 27.2% due to MedTech and dental business mix.

• Net profit for the period was EUR 8.6m, up from EUR 5.1m year-over-year; EPS at EUR 0.02.

Financial highlights

• Q2 revenue grew 15% year-over-year to EUR 104.3m; organic growth was 5%, with acquisitions contributing 12% and currency movements a negative 3%.

• Adjusted EBITDA/EBITA increased 3% to EUR 25.4m; margin at 24.3%, impacted by MedTech orthopedics and dental consolidation.

• Operating profit (EBIT) rose 9% to EUR 14.5m; EBIT margin at 13.9%.

• Cash flow from operating activities reached EUR 22.2m, up from EUR 5.9m in Q2 2024.

• Net debt at EUR 260.6m; leverage at 2.1x pro-forma adjusted EBITDA; cash and cash equivalents at EUR 67.5m.

Outlook and guidance

• Confident in delivering on 2025 and 2030 financial targets, including EUR 300m adjusted EBITDA by 2030.

• Priority is to turn around MedTech orthopedics; no immediate market improvement expected, but actions underway to return to growth.

• Expect continued solid performance in Specialty Pharma, Veterinary Services, and Diagnostics; MedTech dental remains strong.

• Long-term sector outlook remains positive, supported by pet ownership trends and resilient demand.